Methotrexat Sandoz (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a key co‑factor for DNA synthesis. This limits the production of nucleotides needed for cell division, affecting rapidly proliferating cells such as immune cells and cancer cells. The drug also increases extracellular adenosine, providing anti‑inflammatory effects.

The dose of Methotrexat Sandoz is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed regimen can be stated; the prescriber will calculate the appropriate amount and frequency for each patient.

Methotrexat Sandoz is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and death. Women of child‑bearing potential must use effective contraception. Breastfeeding is not recommended, as methotrexate can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methotrexat Sandoz. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Methotrexat Sandoz contains methotrexate, the most widely used antimetabolite for both autoimmune and oncologic diseases. Compared with alternatives such as leflunomide for rheumatoid arthritis or 5‑fluorouracil for certain cancers, methotrexate offers a well‑characterized efficacy profile but may require more intensive monitoring for hepatic and hematologic toxicity.

Methotrexat Sandoz should be stored in a refrigerator at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours and return to refrigeration promptly.

Methotrexat Sandoz is supplied as a sterile injection and may be given intramuscularly, intravenously, or subcutaneously according to the prescriber’s instructions. The route, volume, and infusion rate are selected based on the indication, patient tolerance, and clinical setting.

The most critical adverse events include bone marrow suppression leading to pancytopenia, severe liver injury or fibrosis, pulmonary toxicity such as interstitial pneumonitis, and life‑threatening infections. Patients should be educated to report unexplained fever, persistent cough, jaundice, or unusual bruising promptly.

Methotrexat Sandoz is contraindicated in pregnant or breastfeeding women, patients with severe hepatic or renal impairment, those with active infections, and individuals receiving live vaccines. Caution is also advised for patients with known hypersensitivity to methotrexate or any component of the formulation.